- Home
- LYRA vs NERV Comparison
LYRA vs NERV Comparison
Compare LYRA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- NERV
- Stock Information
- Founded
- LYRA 2005
- NERV 2007
- Country
- LYRA United States
- NERV United States
- Employees
- LYRA N/A
- NERV N/A
- Industry
- LYRA Medical/Dental Instruments
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- NERV Health Care
- Exchange
- LYRA Nasdaq
- NERV Nasdaq
- Market Cap
- LYRA 15.0M
- NERV 12.0M
- IPO Year
- LYRA 2020
- NERV 2014
- Fundamental
- Price
- LYRA $7.05
- NERV $2.25
- Analyst Decision
- LYRA Buy
- NERV Hold
- Analyst Count
- LYRA 2
- NERV 1
- Target Price
- LYRA $16.00
- NERV $5.00
- AVG Volume (30 Days)
- LYRA 28.3K
- NERV 35.1K
- Earning Date
- LYRA 08-12-2025
- NERV 08-14-2025
- Dividend Yield
- LYRA N/A
- NERV N/A
- EPS Growth
- LYRA N/A
- NERV N/A
- EPS
- LYRA N/A
- NERV 1.48
- Revenue
- LYRA $770,000.00
- NERV N/A
- Revenue This Year
- LYRA N/A
- NERV N/A
- Revenue Next Year
- LYRA $139.18
- NERV N/A
- P/E Ratio
- LYRA N/A
- NERV $1.52
- Revenue Growth
- LYRA N/A
- NERV N/A
- 52 Week Low
- LYRA $3.81
- NERV $1.15
- 52 Week High
- LYRA $37.50
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- LYRA 41.94
- NERV 69.92
- Support Level
- LYRA $6.51
- NERV $1.79
- Resistance Level
- LYRA $7.57
- NERV $1.81
- Average True Range (ATR)
- LYRA 0.55
- NERV 0.10
- MACD
- LYRA 0.14
- NERV 0.01
- Stochastic Oscillator
- LYRA 47.71
- NERV 76.56
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.